Search STIM
Neuronetics, Inc.
Nasdaq · CIK 1227636
Last close2.16
Daily change-0.06 (-2.70%)
10 Years gain-92.22%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STIM · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
54.3Momentum
100.0Acceleration
100.0Confidence
67.0Annual Revenue10
Quarterly Revenue37
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.4 / 25
Quality12.5 / 25
Capital Efficiency9.1 / 20
Balance Sheet5.2 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 23.3383 percentage points.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 17.4865 percentage points.
Heavy share dilution · HIGHDiluted share count increased 18.9767%.
Low interest coverage · HIGHInterest coverage is -3.0207x.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM79.48%OK
Revenue CAGR 3Y31.76%OK
Gross Margin47.71%OK
Operating Margin-17.09%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-31.27%OK
Incremental Operating Margin 3Y9.59%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y18.98%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $149.16M | $72.31M | -$31.44M | n/a | n/a | 48.48% | -21.08% | n/a | -32.55% | 65.95M |
| 2025 FY Dec 31, 2024 | $74.89M | $54.16M | -$34.56M | -$31.00M | -$32.46M | 72.32% | -46.15% | -43.35% | -55.61% | 31.73M |
| 2025 FY Dec 31, 2023 | $71.35M | $51.71M | -$30.55M | -$32.04M | -$34.41M | 72.47% | -42.82% | -48.22% | -85.49% | 28.66M |
| 2024 FY Dec 31, 2022 | $65.21M | $49.72M | -$35.11M | -$30.74M | -$34.01M | 76.26% | -53.85% | -52.15% | -113.12% | 26.9M |
| 2023 FY Dec 31, 2021 | $55.31M | $43.66M | -$27.56M | -$27.98M | -$30.34M | 78.93% | -49.83% | -54.85% | -116.06% | 25.48M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $151.43M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-094078, 0001104659-25-105924 |
| Revenue Growth TTM | 79.48% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-094078, 0001104659-25-105924 |
| Revenue CAGR 3Y | 31.76% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-029004 |
| Revenue CAGR 5Y | 24.81% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-029004 |
| Gross Profit CAGR 3Y | 13.29% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-029004 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-094078, 0001104659-25-105924 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 47.71% | Gross Profit / Revenue | OK | 0001104659-26-094078, 0001104659-25-105924 |
| Operating Margin | -17.09% | Operating Income / Revenue | OK | 0001104659-26-094078, 0001104659-25-105924 |
| ROIC | -31.27% | NOPAT / Average Invested Capital | OK | 0001104659-26-094078, 0001104659-25-105924 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-094078 |
| Interest Coverage | -3.02x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1.88x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.31x | (Cash + Short-term Investments) / Total Debt | OK | 0001104659-26-094078 |